Comparative Pharmacology
Head-to-head clinical analysis: PLUVICTO versus VIZAMYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLUVICTO versus VIZAMYL.
PLUVICTO vs VIZAMYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. After binding, the radioactive isotope lutetium-177 emits beta particles, causing DNA damage and cell death.
Vizamyl is a radiopharmaceutical that binds to beta-amyloid plaques in the brain, enabling visualization via PET imaging.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is administered intravenously at a dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, in combination with a gonadotropin-releasing hormone (GnRH) analog or after prior unilateral orchiectomy.
For diagnostic imaging: 370 MBq (10 mCi) administered as a slow intravenous bolus (approximately 1 mL/sec).
None Documented
None Documented
Effective half-life of lutetium-177 is approximately 160 hours (6.67 days), reflecting both physical decay (T1/2 6.647 days) and biological clearance. Clinical context: Due to physical decay, therapeutic radioactivity decreases to <1% after about 45 days.
Terminal elimination half-life is approximately 45-50 minutes in patients with normal renal function, allowing for rapid clearance and early imaging within 4 hours post-injection.
Primarily renal; approximately 60% of administered radioactivity excreted in urine within 24 hours, with gradual elimination thereafter. Biliary/fecal excretion accounts for <15%.
Primarily renal excretion as unchanged drug (90-95%) with the remainder excreted via feces (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical